预约演示
更新于：2025-05-16
Imidafenacin
咪达那新
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 Imidafenacin (JAN/INN)、KRP 197、KRP-197 + [9] |
作用方式 拮抗剂 |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2007-04-18), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS号170105-16-5 |
关联
45
项与 咪达那新 相关的临床试验CTR20242398
咪达那新片在中国健康受试者中的单中心、随机、开放、双周期、双交叉空腹及餐后状态下的生物等效性试验
ChiCTR2300070562
A randomized, open-label, two-formulation, two-period, crossover study of the bioequivalence of a single oral dose of Imidafenacin tablets in fasted and fed healthy Chinese subjects
CTR20202404
咪达那新片（0.1mg）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
100 项与 咪达那新 相关的临床结果
登录后查看更多信息
100 项与 咪达那新 相关的转化医学
登录后查看更多信息
100 项与 咪达那新 相关的专利（医药）
登录后查看更多信息
159
项与 咪达那新 相关的文献（医药）2025-04-01ENVIRONMENTAL RESEARCH
The association of seasonal dietary shift with fecal metabolome and microbiota in the captive Yangtze finless porpoise (Neophocaena asiaeorientalis asiaeorientalis)
Article
作者: Wang, Chaoqun ; Nabi, Ghulam ; Tang, Bin ; Hao, Yujiang ; He, Dekui ; Wan, Xiaoling ; Ur Rahman Shah, Syed Ata ; Wang, Kexiong ; Ahmad, Maaz ; Zheng, Jinsong
The gut microbiota can act as a buffer against changes in energy and food availability and adapt plastically to fluctuations in the host's diet. However, it is unknown how changes in the gut microbiome with the seasons impact microbial metabolism and the accessibility of nutrients to hosts. The study utilized 16S rRNA and UHPLC-MS/MS approaches to examine seasonal fecal metabolome variations in the captive Yangtze finless porpoises (YFPs) to determine if these variations are linked to nutrient intake or gut microbiome composition changes. The YFPs were mostly fed a frozen and live fish diet, with different food intakes yearly. We found that gut microbial diversity remained constant, but community structure varied seasonally. Firmicutes and Cyanobacteria were higher in winter, Actinobacteria in spring and fall, and proteobacteria in summer. The genus Paeniclostridium was significantly higher in the spring season, Romboutsia and Clostridium_sensu_stricto_13 were significantly higher in the summer, while Terrisporobacter and Macrococcus were significantly higher in the fall group. The study reported that seasonal dietary variation significantly impacted the fecal metabolome by affecting the metabolism, including energy, amino acid, carbohydrate, and nucleotide metabolism of the captive YFP. Moreover, significant correlations between metabolome and microbiome were found, and these correlations may indicate that the captive YFP has adapted to cope with dietary variations and enhance energy acquisition. These findings improve our knowledge of the link between microbiota, diet, metabolites, and the physiology of the host and suggest that gut microbial populations may adapt continuously to changes in diet.
2024-06-01Journal of Inclusion Phenomena and Molecular Recognition in Chemistry
Predictors for symptom improvement in overactive bladder patients treated with imidafenacin
作者: Jang, Kyoungha ; Lee, Jeong Zoo ; Park, Yangkyu ; Seong, Wooseop ; Kim, Seunghyeon ; Shin, Dong Gil ; Kim, Hyeon Woo ; Kim, Tae Nam
The objective of this investigation is to ascertain the determinants associated with the amelioration of symptoms in female patients suffering from overactive bladder (OAB) following treatment with 0.2 mg of imidafenacin.The study included 66 female OAB patients who had been prescribed a daily dose of 0.2 mg imidafenacin for a min. of 3 mo, spanning from March 2018 to June 2020.Various clin. parameters including age, coexistence of addnl. voiding symptoms, prior history of urol. surgeries, and responses to the Overactive Bladder Symptom Score questionnaire (OABSS), both pre- and post-initiation of imidafenacin therapy, were evaluated.The mean total OABSS scores recorded before and 3 mo subsequent to imidafenacin therapy were 8.36 ± 3.65 and 5.15 ± 3.22, resp.Following the 3-mo course of imidafenacin treatment, there was a statistically significant improvement in both the total OABSS score and the severity of OAB symptoms (p < 0.001 for both).Prior to treatment initiation, Group B (n = 38) exhibited significantly higher total OABSS scores and subscores compared to Group A (n = 28) (p < 0.05).Multivariable anal. identified the OABSS subscores for items 1 and 3 prior to treatment as significant predictors for the improvement of OAB severity subsequent to imidafenacin therapy (p = 0.046, OR 3.10, 95% CI 1.019-9.440 and p < 0.001, OR 2.77, 95% CI 1.671-4.587, resp.).Consequently, imidafenacin emerges as an efficacious therapeutic agent for alleviating OAB severity in female patients, with the OABSS subscores for items 1 and 3 prior to treatment initiation holding potential utility in predicting the efficacy of imidafenacin in managing OAB.
2024-06-01Drug metabolism and pharmacokinetics
Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder
Article
作者: Yamada, Shizuo ; Tanaka, Shimako ; Akashita, Gaku ; Nakatani, Eriko ; Shiho, Mizuki ; Okura, Takashi
To assess the pharmacologically relevant and selective muscarinic receptor occupancy in the bladder mucosa, we considered not only plasma drug concentrations but also urinary drug concentrations. The purpose of this study was to predict muscarinic receptor occupancy in the human bladder mucosa based on urinary concentrations in response to clinical dosages of antimuscarinic agents used to treat overactive bladder. The calculated mean plasma or serum unbound steady state concentrations were 0.06-11 nM in clinical dosages of five antimuscarinic agents. Urinary concentrations calculated from the mean plasma or serum and renal clearance ranged between 19 nM and 2 μM, which were >10-fold higher than the Ki values for bladder muscarinic receptors excluding propiverine. Bladder mucosal muscarinic receptor occupancy estimated from the urinary concentrations and the Ki values was >90 % at a steady state in clinical dosages of five antimuscarinic agents. The bladder muscarinic receptor occupancy was higher than that in the parotid gland calculated based on the mean plasma or serum unbound concentrations and Ki values for muscarinic receptors in the parotid gland. These results suggest that sufficient and selective muscarinic receptor occupancy by antimuscarinic agents, to exert pharmacological effects, in the bladder mucosa can be predicted using urinary concentrations.
1
项与 咪达那新 相关的新闻（医药）2024-01-15
·信狐药迅
100 项与 咪达那新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 日本 | 2007-04-18 | |
| 膀胱过度活动症 | 日本 | 2007-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿频 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 急迫性尿失禁 | 临床1期 | 中国 | 2015-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 300 | 夢艱繭選鹹艱膚齋鹹鹽(鑰簾壓觸糧艱簾襯積遞) = 廠獵觸願憲壓築鹹範鑰 餘繭觸鏇繭醖構夢積繭 (鏇齋艱構膚鹽醖繭願壓, 2.2) 更多 | 非劣 | 2019-06-01 | |||
夢艱繭選鹹艱膚齋鹹鹽(鑰簾壓觸糧艱簾襯積遞) = 壓繭鏇觸選鏇願遞鏇糧 餘繭觸鏇繭醖構夢積繭 (鏇齋艱構膚鹽醖繭願壓, 1.8) 更多 | |||||||
临床3期 | 300 | (Uritos®) | 壓願膚廠鑰襯鑰築遞積(艱襯願觸築鏇鑰範壓廠) = 糧選構齋鹹壓積膚夢鬱 壓範蓋襯鑰餘鹹淵衊齋 (鑰顧糧選獵夢製願蓋糧, 3.5) 更多 | - | 2019-05-21 | ||
(Urotol®) | 壓願膚廠鑰襯鑰築遞積(艱襯願觸築鏇鑰範壓廠) = 膚壓鬱鏇鑰製窪鏇窪範 壓範蓋襯鑰餘鹹淵衊齋 (鑰顧糧選獵夢製願蓋糧, 2.7) 更多 | ||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 積選遞選積糧鹹艱獵艱 = 壓衊膚廠襯廠膚窪廠鹽 蓋選窪廠艱膚糧顧遞蓋 (憲膚廠範選襯壓顧鹽鑰, 簾衊遞鑰齋窪蓋網選簾 ~ 構鹽齋選夢積蓋餘願糧) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 積選遞選積糧鹹艱獵艱 = 窪衊餘糧獵糧鹽淵衊積 蓋選窪廠艱膚糧顧遞蓋 (憲膚廠範選襯壓顧鹽鑰, 鬱壓鏇醖製壓齋顧鹹壓 ~ 築製窪構壓顧夢繭鹽範) 更多 | ||||||
N/A | 308 | 觸醖衊糧網淵醖鹽蓋範(餘衊構夢餘網願廠網膚) = 觸壓遞遞夢齋淵襯製齋 鏇壓壓襯鹹鏇願窪襯壓 (範憲遞淵壓襯獵醖願憲, 1.47 ~ 2.74) 更多 | 积极 | 2013-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用